Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
CA 2498089 A1 · Owner: Bebernitz, Gregory Raymond · Inventors: Bebernitz, Gregory Raymond
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of the formula (I) provide pharmacological agents which are glucokinase activators and thus may be employed for the treatment of glucokinase mediated conditions. Accordingly the compounds of formula (I) may , be employed for prevention and treatment of impaired glucose tolerance Type 2 , diabetes and obesity, wherein Q is formula (II) or formula (III) R is a , radical of the formula (IV) or (V) or (VI) wherein Y R1-R6, R12 and R13 are , as defined in the description.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 2, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.